E-Newsletter - January 2022


The Alliance for Clinical Trials in Oncology and Alliance Foundation Trials, LLC presented an array of novel data from many of its hematology studies during the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition December 11-14 in Atlanta, GA. Many of these data will help change the delivery of hematologic cancer care or help elucidate the underlying cause and effect relationships seen in this field.

Here's a snapshot of Alliance and AFT abstracts.

Performance of Standard Prognostic Models in Older Adults Receiving Ibrutinib for Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL): A Post Hoc Analysis of Alliance A041202 Phase 3 Trial
Abstract #: 642
Lead author: Inhye E. Ahn

Randomized Phase II/III  Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701
Abstract #: 626
Lead author: Jeremy S. Abramson

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of Griffin
Abstract: #653
Lead author: Larry D. Anderson, Jr.

Comparative Outcomes and Molecular Response Predictors of IDH1/2-mutated Adult Acute Myeloid Leukemia (AML) Patients (Pts) after Frontline Treatment with Intensive Induction Chemotherapy (IC), Targeted Inhibitors, or Hypomethylating Agents (HMA) (Alliance)
Abstract: #617
Lead author: Uma Borate

Multi-dimensional Analysis of Adult Acute Myeloid Leukemia (AML) Landscape Cross-Continents Reveals Age-associated Trends in Mutations and Outcomes (Alliance)
Abstract: #613
Lead author: Monica Cusan

Epigenetic Phenocopying Expands Molecular Risk Assessment in Acute Myeloid Leukemia (Alliance)
Abstract: #617
Lead author: Brian Giacopelli

High Early Death Rates, Treatment Resistance and Short Survival of Very Young Black Adolescent and Young Adults (AYAs) with Acute Myeloid Leukemia (AML) (Alliance)
Abstract: #613
Lead author: Karilyn Larkin

Enrollment Characteristics and Outcomes of Hispanic and Black AYA ALL Patients Enrolled on a U.S. Intergroup Clinical Trial: A Comparison of the CALGB 10403 Cohort with U.S. Population-Level Data (Alliance)
Abstract: #905
Lead author: Lori Muffly

Social Deprivation Independently Predicts Survival in Younger Patients with Acute Myeloid Leukemia (Alliance)
Abstract: #906
Lead author: Melanie T Rebechi

Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy
Abstract: #642
Lead author: Jennifer A. Woyach


For other articles in this issue of the Alliance E-News newsletter, see below.